BioSpace News Archive

Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs)

Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R) today announced that it has entered into an agreement with Defence R&D Canada - Suffield Research Centre (“DRDC”), an agency of the Canadian Department of National Defence, to evaluate Bucillamine as a potential treatment for nerve agent exposure.

Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that the first patient has been dosed with BDC-3042 in the single-agent dose-escalation portion of this first-in-human Phase 1/2 clinical study.

Evelo Biosciences, Inc. (Nasdaq:EVLO) (“Evelo” or the “Company”), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis (SINTAX), today announced top-line results from its Phase 2 clinical study with EDP2939 in moderate psoriasis.

Access Vascular, Inc. (AVI), a company addressing the most common and costly vascular access complications with its advanced biomaterial platform, today announced findings from a new, in vitro study showing a significant reduction in bacterial adhesion and thrombus accumulation in peripherally inserted central catheters (PICC) and midline catheters with AVI’s MIMIX™ hydrophilic biomaterial (HBM).

STAAR Surgical Company, a leading developer, manufacturer and marketer of implantable lenses for the eye, is celebrating the 30th anniversary of its proprietary Implantable Collamer® Lens.

Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”) today announced that the European Medicines Agency (“EMA”) Committee for Orphan Medicinal Products has granted orphan drug designation to LSTA1, the Company’s lead product candidate for the treatment of pancreatic cancer.

Hansa Biopharma announced results from an extended pooled analysis using data from the 17-HMedIdeS-14 study,1 an international long-term follow-up study of patients who have received a kidney transplant following desensitization with imlifidase, showing sustained positive outcomes out to 5 years in the majority of highly sensitized patients who received an imlifidase-enabled kidney transplant.

Teva Pharmaceutical Industries Ltd. announce that data from the UNITE study presented at the World Congress of Neurology in Montreal, Canada, show that AJOVY® reduced migraine attacks and depression symptoms in migraine patients with major depressive disorder.

Poolbeg Pharma announces that it has signed a strategic collaboration agreement with a Nasdaq listed biopharma company for the development of an optimised oral drug to treat a metabolic condition.